Hepatitis B virus infection among Nigerian pediatric population

Stephen Oluwasegun Adetunji1, Adebukola Ajite2, Blessing Ifeoluwa Adetunji3

  • 1Medical Microbiology and Parasitology Department, University College Hospital, Ibadan, Nigeria.

Insights

Hepatitis B virus (HBV) infection shows intermediate endemicity in asymptomatic Nigerian children, with higher rates in unvaccinated individuals and older age groups. Continued vaccination and public awareness are crucial.

Area of Science:

  • Hepatology
  • Pediatrics
  • Infectious Diseases

Background:

  • Hepatitis B infection remains a significant global health issue despite vaccination efforts.
  • The prevalence and burden of Hepatitis B virus (HBV) infection in asymptomatic pediatric populations require ongoing evaluation.

Purpose of the Study:

  • To assess the prevalence and epidemiological characteristics of Hepatitis B infection among asymptomatic children in Nigeria.
  • To identify risk factors associated with HBV infection in the pediatric population.

Main Methods:

  • A cross-sectional study involving 206 asymptomatic children visiting a hospital between March and August 2018.
  • Blood samples were screened for Hepatitis B surface antigen (HBsAg) after informed consent.
  • Data were analyzed using chi-square statistics to determine infection rates and associations.

Main Results:

  • The overall prevalence of HBsAg positivity was 2.9% (6/206).
  • Higher infection rates were observed in males (4%) compared to females (1.9%) and in the 13-18 years age group (6.6%).
  • Unvaccinated children exhibited a higher HBV infection rate (4.2%) than vaccinated children (1.1%).

Conclusions:

  • Hepatitis B infection demonstrates intermediate endemicity within the studied Nigerian pediatric population.
  • Vaccination status and age are significant factors influencing HBV infection rates in children.
  • Sustained vaccination programs and enhanced public awareness, particularly among women of marriageable age, are recommended to control HBV transmission.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
124
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
101
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
132
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
151